These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26646993)

  • 1. ACR Practice Parameter for the Performance of Therapy With Unsealed Radiopharmaceutical Sources.
    Spratt DE; Zaki BI; Franc BL; Hartford AC; Osborne JR
    Clin Nucl Med; 2016 Feb; 41(2):106-17. PubMed ID: 26646993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.
    Henkin RE; Del Rowe JD; Grigsby PW; Hartford AC; Jadvar H; Macklis RM; Parker JA; Wong JY; Rosenthal SA
    Clin Nucl Med; 2011 Aug; 36(8):e72-80. PubMed ID: 21716005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223.
    Hurwitz M; Buscombe JR; Jacene HA; Klitzke AK; Lamonica D; Lu Y; Pryma DA; Rohren EM; Speer TW; Subramaniam RM; Thompson HM; Tomblyn MB; Wong WW; Xiao Y; Banks KP; Brown RKJ
    Am J Clin Oncol; 2020 Aug; 43(8):539-544. PubMed ID: 32520788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals.
    Wallner PE; Yoo DC; Calais J; Escorcia FE; Mari Aparici C; Michalski J; Morris M; Morris ZS; Pryma D; Rabatic BM; Sharma N; Vapiwala N; Ghesani MV; Subramaniam RM; Small W; Schechter NR
    Am J Clin Oncol; 2024 Apr; 47(4):169-176. PubMed ID: 38131352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.
    Dillehay GL; Ellerbroek NA; Balon H; Brill DR; Grigsby PW; Macklis RM; Mauch PM; Mian TA; Potters L; Silberstein EB; Williams TR; Wong JC; Gaspar LE;
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1299-307. PubMed ID: 16472933
    [No Abstract]   [Full Text] [Related]  

  • 6. [Development of a system for risk analysis in treatment with unsealed radioactive substances in nuclear medicine].
    Kotzerke J; Fetzer P; Grosche-Schlee S; Hanel A; Freudenberg R; Brogsitter C
    Nuklearmedizin; 2020 Apr; 59(2):60-78. PubMed ID: 32126578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical dosimetry in the treatment of bone tumors: old and new agents.
    Hindorf C; Flux GD; Ibisch C; Kraeber Bodéré F
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):198-204. PubMed ID: 21386790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiopharmaceuticals for palliation of painful osseous metastases.
    Smith H; Navani A; Fishman SM
    Am J Hosp Palliat Care; 2004; 21(4):303-13. PubMed ID: 15315195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review.
    van der Pol J; Vöö S; Bucerius J; Mottaghy FM
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1234-1243. PubMed ID: 28303300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Draft guidelines regarding appropriate use of (131)I-MIBG radiotherapy for neuroendocrine tumors : Guideline Drafting Committee for Radiotherapy with (131)I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine.
    Kinuya S; Yoshinaga K; Higuchi T; Jinguji M; Kurihara H; Kawamoto H;
    Ann Nucl Med; 2015 Jul; 29(6):543-52. PubMed ID: 25773397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Release of patients after therapy with unsealed radionuclides.
    International Commission on Radiological Protection
    Ann ICRP; 2004; 34(2):v-vi, 1-79. PubMed ID: 15571759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain.
    Paes FM; Serafini AN
    Semin Nucl Med; 2010 Mar; 40(2):89-104. PubMed ID: 20113678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of adverse events to radiopharmaceuticals from 2007 to 2011.
    Silberstein EB
    J Nucl Med; 2014 Aug; 55(8):1308-10. PubMed ID: 24876206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of reported incidents involving radiopharmaceuticals for the development of intervention strategies.
    Charlton MA; Emery RJ
    Health Phys; 2001 Nov; 81(5):585-91. PubMed ID: 11669213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene manipulation to enhance MIBG-targeted radionuclide therapy.
    Mairs RJ; Fullerton NE; Cosimo E; Boyd M
    Nucl Med Biol; 2005 Oct; 32(7):749-53. PubMed ID: 16243651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 186Re-HEDP for metastatic bone pain in breast cancer patients.
    Lam MG; de Klerk JM; van Rijk PP
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACR/ABR clinical statement on credentialing and privileging of radiologists for therapeutic nuclear medicine.
    ; Brown ML; Guiberteau MJ; Oates ME
    J Am Coll Radiol; 2013 Oct; 10(10):774-80. PubMed ID: 24001693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aptamares: a novel class of radiopharmaceutical with diagnostic and therapeutic potential.
    Guhlke S; Famulok M; Biersack HJ
    Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1441-3. PubMed ID: 14658436
    [No Abstract]   [Full Text] [Related]  

  • 20. Strengthening radiopharmacy practice in IAEA Member States.
    Duatti A; Bhonsle U
    Semin Nucl Med; 2013 May; 43(3):188-94. PubMed ID: 23561456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.